Indegene Healthcare UK Limited is set to acquire 100% equity in two UK-based entities: DT Associates Research and Consulting Services Limited and Trilogy Writing and Consulting Limited. This transaction, signed on March 01, 2026, constitutes an internal restructuring, as both target companies will transition to become wholly owned subsidiaries of Indegene Healthcare UK Limited. DT UK reported revenue of GBP 6.4 million in its latest full financial year.
Acquisition of UK Consulting Firms
Indegene Healthcare UK Limited, a wholly owned subsidiary of Indegene Ireland Limited, has entered into a Share Purchase Agreement (SPA) on March 01, 2026, to acquire two separate UK entities. This transaction is detailed as an internal restructuring exercise.
The entities being acquired are:
- Target Company – 1: DT Associates Research and Consulting Services Limited (DT UK).
- Target Company – 2: Trilogy Writing and Consulting Limited (Trilogy UK).
Upon completion, both DT UK and Trilogy UK will transition from their current ownership structures to become wholly owned subsidiaries of Indegene Healthcare UK Limited.
Target Entity Profiles and Financial Snapshot
Both target companies operate in the Healthcare industry, providing specialized services to the life science and pharmaceutical sectors.
DT Associates Research and Consulting Services Limited (DT UK)
- Business: Provides analytics, technology, commercial, medical, regulatory, and safety services for life science and healthcare organizations.
- Incorporation Date: 25-Jul-2013.
- Acquisition Price: £2,001,000.
- Last Full Financial Year Turnover (FY 2024-25): GBP 6,400,711. (Note: Turnover for the prior year, FY 2023-24, was GBP 9,240,729).
Trilogy Writing & Consulting Limited (Trilogy UK)
- Business: Provides writing and training services specifically for the pharmaceutical industry.
- Incorporation Date: 19-Jan-2011.
- Acquisition Price: £702,348.
- Last Full Financial Year Turnover (FY ending March 2025): GBP 2,340,488. (Note: Turnover for the prior period ending December 2024 was GBP 1,855,915).
Transaction Details
The acquisition involves 100% of the shareholding/control of both DT UK and Trilogy UK being transferred to Indegene Healthcare UK Limited. The consideration for this transaction is in Cash.
Although these transactions fall within the definition of related party transactions, it is confirmed that the group companies hold no interest in the entities being acquired, and the transactions are being executed on an arm’s length basis.
The indicative time period for the completion of this acquisition is set for 31 March 2026.
Source: BSE
